BIOMAT Database Logo BIOMAT Database Logo

Induction of ovulation in women undergoing assisted reproductive techniques: recombinant human FSH (follitropin alpha) versus highly purified urinary FSH (urofollitropin HP). 2000

E Lenton, and A Soltan, and J Hewitt, and A Thomson, and W Davies, and N Ashraf, and V Sharma, and L Jenner, and W Ledger, and E McVeigh
Sheffield Fertility Centre, Sheffield, S7 1RA, Reproductive Medicine Unit, Liverpool Women's Hospital, Liverpool L8 7SS, UK.

This multicentre, open, randomized, study compared the efficacy and safety of recombinant follicle stimulating hormone (rFSH; follitropin alpha) with highly purified urinary human FSH (uFSH; urofollitropin HP) in women undergoing ovulation induction for assisted reproductive techniques. Following long down-regulation with buserelin, patients received two ampoules of 75 IU (150 IU) s.c. rFSH or highly purified uFSH for 6 days, after which the dose could be increased until they fulfilled the criteria for human chorionic gonadotrophin (HCG) administration. Of 168 patients recruited, 155 received at least one dose of FSH, and 137 received HCG [68: rFSH (85%); 69: uFSH (92%)]. Following oocyte retrieval and fertilization, up to three embryos were replaced/patient and luteal support was given. The mean number of oocytes retrieved/patient was 10.2 +/- 6.0 for rFSH patients compared with 10.8 +/- 6.1 in the uFSH group (not significant). There was a trend towards fewer ampoules used (22.3 +/- 6.5 versus 24.3 +/- 6.5), higher pregnancy (44.3 versus 41.4%) and live birth rates (33.8 versus 26.7%), as well as a lower miscarriage rate (0.0 versus 16.7%) in favour of rFSH. However, no significant differences in efficacy parameters were recorded. Ovarian hyperstimulation syndrome occurred in 8.6% and 7.9% of rFSH and uFSH patients respectively. In conclusion, this protocol was effective in inducing multiple follicular development and high numbers of oocytes were retrieved with both drugs.

UI MeSH Term Description Entries
D008596 Menotropins Extracts of urine from menopausal women that contain high concentrations of pituitary gonadotropins, FOLLICLE STIMULATING HORMONE and LUTEINIZING HORMONE. Menotropins are used to treat infertility. The FSH:LH ratio and degree of purity vary in different preparations. Gonadotropins, Human Menopausal,Human Menopausal Gonadotropin,CP-89044,CP-90033,HMG Ferring,HMG Lepori,HMG Massone,Humegon,Menogon,Menopur,Menotrophin,Normegon,ORG-31338,Pergonal,Pergonal-500,CP 89044,CP 90033,CP89044,CP90033,Gonadotropin, Human Menopausal,Human Menopausal Gonadotropins,Lepori, HMG,Menopausal Gonadotropin, Human,ORG 31338,ORG31338,Pergonal 500,Pergonal500
D010062 Ovulation Induction Techniques for the artifical induction of ovulation, the rupture of the follicle and release of the ovum. Ovarian Stimulation,Ovarian Stimulations,Stimulation, Ovarian,Stimulations, Ovarian
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002064 Buserelin A potent synthetic analog of GONADOTROPIN-RELEASING HORMONE with D-serine substitution at residue 6, glycine10 deletion, and other modifications. Bigonist,Buserelin Acetate,HOE-766,Profact,Receptal,Suprecur,Suprefact,Tiloryth,Acetate, Buserelin,HOE 766,HOE766
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004622 Embryo, Mammalian The entity of a developing mammal (MAMMALS), generally from the cleavage of a ZYGOTE to the end of embryonic differentiation of basic structures. For the human embryo, this represents the first two months of intrauterine development preceding the stages of the FETUS. Embryonic Structures, Mammalian,Mammalian Embryo,Mammalian Embryo Structures,Mammalian Embryonic Structures,Embryo Structure, Mammalian,Embryo Structures, Mammalian,Embryonic Structure, Mammalian,Embryos, Mammalian,Mammalian Embryo Structure,Mammalian Embryonic Structure,Mammalian Embryos,Structure, Mammalian Embryo,Structure, Mammalian Embryonic,Structures, Mammalian Embryo,Structures, Mammalian Embryonic
D004624 Embryo Transfer The transfer of mammalian embryos from an in vivo or in vitro environment to a suitable host to improve pregnancy or gestational outcome in human or animal. In human fertility treatment programs, preimplantation embryos ranging from the 4-cell stage to the blastocyst stage are transferred to the uterine cavity between 3-5 days after FERTILIZATION IN VITRO. Blastocyst Transfer,Tubal Embryo Transfer,Tubal Embryo Stage Transfer,Embryo Transfers,Transfer, Embryo,Transfers, Embryo
D005260 Female Females
D005300 Fertility Agents, Female Compounds which increase the capacity to conceive in females. Fertility Agents, Female, Hormonal,Fertility Agents, Female, Synthetic,Infertility Agents, Female,Female Fertility Agents, Synthetic,Infertility Drugs, Female,Synthetic Female Fertility Agents,Agents, Female Fertility,Agents, Female Infertility,Drugs, Female Infertility,Female Fertility Agents,Female Infertility Agents,Female Infertility Drugs

Related Publications

E Lenton, and A Soltan, and J Hewitt, and A Thomson, and W Davies, and N Ashraf, and V Sharma, and L Jenner, and W Ledger, and E McVeigh
Efficacy of Highly Purified Urinary FSH versus Recombinant FSH in Chinese Women over 37 Years Undergoing Assisted Reproductive Techniques.
January 2015, International journal of fertility & sterility,
E Lenton, and A Soltan, and J Hewitt, and A Thomson, and W Davies, and N Ashraf, and V Sharma, and L Jenner, and W Ledger, and E McVeigh
Recombinant human follicle stimulating hormone (r-hFSH; Gonal-F) versus highly purified urinary FSH (Metrodin HP): results of a randomized comparative study in women undergoing assisted reproductive techniques.
October 1997, Human reproduction (Oxford, England),
E Lenton, and A Soltan, and J Hewitt, and A Thomson, and W Davies, and N Ashraf, and V Sharma, and L Jenner, and W Ledger, and E McVeigh
Comparative assessment of the consistency and quality of a highly purified FSH extracted from human urine (urofollitropin) and a recombinant human FSH (follitropin alpha).
August 2006, Reproductive biomedicine online,
E Lenton, and A Soltan, and J Hewitt, and A Thomson, and W Davies, and N Ashraf, and V Sharma, and L Jenner, and W Ledger, and E McVeigh
A double-blind, randomized study to compare recombinant human follicle stimulating hormone (FSH; Gonal-F) with highly purified urinary FSH (Metrodin) HP) in women undergoing assisted reproductive techniques including intracytoplasmic sperm injection. The French Multicentre Trialists.
March 2000, Human reproduction (Oxford, England),
E Lenton, and A Soltan, and J Hewitt, and A Thomson, and W Davies, and N Ashraf, and V Sharma, and L Jenner, and W Ledger, and E McVeigh
Recombinant versus highly-purified, urinary follicle-stimulating hormone (r-FSH vs. HP-uFSH) in ovulation induction: a prospective, randomized study with cost-minimization analysis.
July 2006, Reproductive biology and endocrinology : RB&E,
E Lenton, and A Soltan, and J Hewitt, and A Thomson, and W Davies, and N Ashraf, and V Sharma, and L Jenner, and W Ledger, and E McVeigh
Ovulation induction in clomiphene-resistant anovulatory women: differential follicular response to purified urinary follicle-stimulating hormone (FSH) versus purified urinary FSH and luteinizing hormone.
May 1985, The Journal of clinical endocrinology and metabolism,
E Lenton, and A Soltan, and J Hewitt, and A Thomson, and W Davies, and N Ashraf, and V Sharma, and L Jenner, and W Ledger, and E McVeigh
Recombinant versus urinary human chorionic gonadotrophin for ovulation induction in assisted conception.
April 2005, The Cochrane database of systematic reviews,
E Lenton, and A Soltan, and J Hewitt, and A Thomson, and W Davies, and N Ashraf, and V Sharma, and L Jenner, and W Ledger, and E McVeigh
Recombinant human FSH versus highly purified urinary FSH: a randomized study in intrauterine insemination with husbands' spermatozoa.
June 2000, Human reproduction (Oxford, England),
E Lenton, and A Soltan, and J Hewitt, and A Thomson, and W Davies, and N Ashraf, and V Sharma, and L Jenner, and W Ledger, and E McVeigh
Recombinant FSH versus urinary gonadotrophins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovary syndrome.
January 2001, The Cochrane database of systematic reviews,
E Lenton, and A Soltan, and J Hewitt, and A Thomson, and W Davies, and N Ashraf, and V Sharma, and L Jenner, and W Ledger, and E McVeigh
WITHDRAWN: Recombinant FSH versus urinary gonadotrophins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovary syndrome.
August 2015, The Cochrane database of systematic reviews,
Copied contents to your clipboard!